The company reported a net loss of $141.6 million, or $1.20 per share, swinging from a profit of $137 million in the same period last year. This result fell sharply below Wall Street expectations, as analysts polled by FactSet had anticipated earnings of $1.88 per share. The deficit was largely attributed to $284.9 million in research and development costs tied to the December acquisition of Surf Bio.

Revenue Growth vs. Acquisition Costs

Despite the bottom-line miss, Halozyme’s top-line performance remained strong. Revenue surged 52% to $451.8 million, outperforming analyst estimates of $435.7 million. This growth was fueled by robust product sales and increased royalty revenue. Chief Executive Helen Torley noted that the integration of Surf Bio’s hyperconcentration technology is a strategic move to diversify the company's long-term drug delivery portfolio and royalty streams.

2024 Outlook Reaffirmed

Management maintained its full-year guidance despite the quarterly volatility. The company expects adjusted earnings per share between $7.75 and $8.25 on revenue of up to $1.81 billion. Investors reacted to the immediate earnings miss, sending shares down 8.8% to $73.42 on Wednesday, though the stock remains up 27% over the past twelve months.